ERBB2 and breast carcinoma: NCT-58 suppresses HER2-positive breast cancer cells with simultaneous inhibition of important trastuzumab resistance factors including HER2/HER3/Akt and truncated p95HER2 as well as downregulation of Ras/Raf/Mek/Erk.